English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

This study was designed to investigate the greatly reduced activities of hepatic lipase and lipoprotein lipase in postheparin plasma of patients with glycogen storage disease (GSD). Evidence for the presence of a circulating inhibitor in the plasma of GSD patients prior to the establishment of metabolic control was provided by the following observations. The hepatic lipase activity from patients with GSD gave a nonlinear relationship with time, maximum activity being obtained after 5 min whereas normal postheparin plasma showed a linear relationship for at least 20 min. The addition of GSD plasma to a normal postheparin plasma resulted in inhibition of the normal postheparin lipolytic activity. The inhibition showed a dose response, with 10 and 30 microliter of the GSD plasma giving 22 and 65% inhibition after 20 min, respectively. Serial dilution of GSD postheparin plasma gave increasing activity of hepatic lipase when expressed per ml of plasma. Thus, a 1:100 dilution gave a normal activity of 15 mumol/ml/h whereas a 1:10 dilution gave less than 10% of this activity. After affinity chromatography of the GSD postheparin plasma on heparin/Sepharose, the inhibition was removed and a normal lipolytic activity was obtained.

pediatric research

The Activity of Hepatic Lipase and Lipoprotein Lipase in Glycogen Storage Disease: Evidence for a Circulating Inhibitor of Postheparin Lipolytic Activity